RCEL at a glance
AVITA Medical, Inc. (RCEL, SEC CIK 1762303) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 11, 2026 and Form 4 insider filings as recently as August 24, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), AVITA Medical, Inc. (RCEL) reported revenue of $71.6 million (up 11.5% from FY2024) and a net loss of $48.6 million. Diluted EPS was -$1.74.
- As of June 30, 2026, 15 institutional investment managers tracked by SignalX reported holding AVITA Medical, Inc. (RCEL) shares worth $11.8 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by O'Toole David D on June 12, 2026 of 2,000 shares at $3.97 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $71.6M
- +11.5% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 15 funds
- $11.8M · −2 vs prior quarter
- Latest 8-K
- Aug 11, 2026
- Item 1.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Multi-product acute wound care platform focused on autologous cell harvesting technology RECELL plus complementary wound matrices
- New products: Commercial launch of Cohealyx collagen dermal matrix (Apr 2025) and FDA approval/commercial rollout of RECELL GO mini for smaller wounds (Dec 2024)
- Strategic shift: Expansion from burn centers into trauma and surgical wound markets with broadened RECELL indications for full-thickness skin defects
- Quantitative metric: Employee count approx. 226 as of Dec 31, 2025; multiple multi-year distribution and manufacturing agreements for PermeaDerm and Cohealyx
- Noteworthy fact: CMS New Technology Add-On Payment (NTAP) approval effective Oct 1, 2025 for RECELL in inpatient non-thermal full-thickness skin defects
Risk Factors
- Regulatory risk: dependency on FDA PMA for RECELL, risk of modification/suspension/revocation impacting U.S. operations
- Macroeconomic risk: $60M five-year senior secured credit facility with Perceptive, subject to net revenue covenants and rising interest rate exposure
- Supply chain risk: single-sourcing some critical material components since 2023, risking production delays and cost increases
- Competitive risk: rivals with greater financial resources could develop products rendering RECELL obsolete
- Financial risk: cumulative deficit $408.4M, net loss $48.6M in 2025, with continuing operating losses and cash flow insufficiency to service debt
Management Discussion & Analysis
- Revenue $71.6M in 2025, up 11% YoY from $64.3M in 2024, driven by deeper penetration and new accounts
- Gross margin 82.1% in 2025 vs 85.8% in 2024; decrease due to product mix and higher inventory reserve
- Best segment: RECELL products gross margin 84.3%; Cohealyx and PermeaDerm at 50% and 60% ASP respectively reducing overall margin
- Operating expenses $101.4M in 2025, down 9% YoY from $111.8M; sales & marketing down 9% to $53.1M, G&A down 18% to $27.3M; R&D up 2% to $20.8M
- Net loss $48.6M in 2025, improved 21% vs $61.8M loss in 2024
- Cash and equivalents $10.2M, marketable securities $7.9M at end 2025; new $60M credit facility closed Jan 2026 with $50M funded, refinancing prior debt
- Key risk: ongoing debt covenants require TTM revenue minimums ($68.5M Q1 2026, $73M full year), substantial doubt about going concern due to recurring losses and debt obligations
- Positive outlook supported by FDA NTAP reimbursement for RECELL (effective Oct 2025-Sept 2026) and CE Mark for RECELL GO in EU
AI summary of the RCEL 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No material risk-factor changes from the 2025 Annual Report
- Carried-forward business, liquidity, operational, regulatory, and market risks remain applicable
- Potential adverse effects on financial condition, liquidity, results of operations, and capital position
- Actual results may differ materially from historical results and forward-looking statements
AI summary of the RCEL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- $500,000 fee secures first-offer and refusal rights for potential EU, U.K., and Australian territory expansion
- AVITA’s PermeaDerm revenue share rises to 67% for sheets and 80% for gloves
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 with detailed financial results
Item EX-99.1: Item EX-99.1
- Q2 revenue reached a record $21.7M, up 18% year over year and 13% sequentially, led by RECELL at $18.5M
- Gross margin expanded to 81.9% from 81.2%, while operating expenses fell 6% to $24.6M
Item 5.07: Submission of Matters to a Vote of Security Holders
- Annual advisory votes on named executive compensation selected by stockholders
- Frequency vote totals: 1 year 9,545,151; 2 years 924,743; 3 years 650,252
AI summaries of RCEL 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for RCEL
Don't miss the next RCEL filing
- Alerts as it files. A push when RCEL files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut RCEL, by share count.
- Ask anything. An AI agent that reads every RCEL filing and answers with sources.
RCEL alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| O'Toole David D | A | Jun 12, 2026 | 2,000 | $3.97 |
| O'Toole David D | Buy | Jun 12, 2026 | 2,000 | $3.97 |
| Woody Joseph Fralin | Buy | Jun 9, 2026 | 5,000 | $4.20 |
| Woody Joseph Fralin | Buy | Jun 9, 2026 | 5,000 | $4.18 |
| Woody Joseph Fralin | Buy | Jun 9, 2026 | 5,200 | $4.00 |
| Woody Joseph Fralin | Buy | Jun 3, 2026 | 5,000 | $4.10 |
| Woody Joseph Fralin | Buy | Jun 3, 2026 | 5,000 | $4.09 |
| Woody Joseph Fralin | Buy | Jun 2, 2026 | 5,000 | $4.21 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $50.1M | $64.3M | $71.6M |
| Gross Profit | - | $55.2M | $58.8M |
| Operating Income | - | -$56.6M | -$42.5M |
| Net Income | - | -$61.8M | -$48.6M |
| Gross Margin | - | 85.8% | 82.1% |
| Op. Margin | - | -88.1% | -59.4% |
| Net Margin | - | -96.3% | -67.8% |
| Balance Sheet | |||
| Total Assets | - | $79.7M | $56.4M |
| Equity | - | $4.5M | -$16.6M |
| ROE | - | -1374.6% | 291.8% |
| Per Share | |||
| EPS | - | $-2.39 | $-1.74 |
| Cash Flow | |||
| Operating CF | - | -$48.9M | -$31.2M |
| CapEx | $1.4M | $9.2M | $1.0M |
Source: XBRL data in AVITA Medical, Inc. (RCEL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate RCEL share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 15 | $11.8M |
| Q1 2026 | 17 | $13.7M |
| Q4 2025 | 17 | $12.7M |
| Q3 2025 | 17 | $19.2M |
| Q2 2025 | 21 | $27.7M |
| Q1 2025 | 17 | $23.6M |
| Q4 2024 | 12 | $31.7M |
| Q3 2024 | 10 | $11.0M |
- AQR Capital Management+226.7K (+240%)
- Morgan Stanley+42.8K (+27%)
- FMR LLC (Fidelity)+3.9K (+14%)
- Ameriprise Financial+259 (+1%)
- BlackRock−568.2K (-50%)
- State Street Corp−300.0K (-70%)
- Northern Trust−114.2K (-62%)
- Goldman Sachs Group−23.1K (-23%)
- Bank of America Corp−10.5K (-17%)
- Millennium Management+15.4K
- Vanguard Portfolio Management LLC−82.3K
- BNY Mellon−29.9K
- Citigroup−738
Source: 13F-HR filings on SEC EDGAR (aggregated from 126 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
RCEL filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Aug 24, 2026 | - | - | - |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 8-K | Jun 8, 2026 | - | Analysis | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 19, 2026 | - | - | |
| 8-K | May 14, 2026 | - | Analysis | |
| 10-Q | May 14, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 1, 2026 | - | Analysis | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
- SKIN · Beauty Health CoSurgical & Medical Instruments & Apparatus
RCEL SEC filings: frequently asked questions
Which institutions hold RCEL stock?
As of June 30, 2026, the largest AVITA Medical, Inc. (RCEL) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($5.5 million), BlackRock ($2.3 million), AQR Capital Management ($1.3 million), Morgan Stanley ($828,000), State Street Corp ($533,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was RCEL's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), AVITA Medical, Inc. (RCEL) reported revenue of $71.6 million (up 11.5% from FY2024) and a net loss of $48.6 million. Diluted EPS was -$1.74. The figures come from the XBRL data in the 10-K.
What are the main risks in RCEL's latest 10-K?
In the 10-K filed February 12, 2026, AVITA Medical, Inc. (RCEL) flagged: Regulatory risk: dependency on FDA PMA for RECELL, risk of modification/suspension/revocation impacting U.S. operations. Macroeconomic risk: $60M five-year senior secured credit facility with Perceptive, subject to net revenue covenants and rising interest rate exposure. (AI summary of the Risk Factors section.)
What did RCEL report in its latest 8-K?
AVITA Medical, Inc. (RCEL) filed an 8-K on August 11, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). $500,000 fee secures first-offer and refusal rights for potential EU, U.K., and Australian territory expansion.
What are the latest RCEL SEC filings?
AVITA Medical, Inc. (RCEL) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 11, 2026 and a Form 4 insider filing on August 24, 2026.
What is RCEL's SEC CIK number?
AVITA Medical, Inc. (RCEL)'s SEC Central Index Key (CIK) is 1762303. EDGAR lists every RCEL filing under that number.
Ask anything about RCEL
The research agent reads RCEL's filings, financials, insider trades and 13F holders, then answers with sources.